PO.MD01.02 · 分子诊断与数据
EGFR 突变亚型改变了 TP53 功能缺失对肺癌脑转移和生存的临床影响
EGFR mutation subtype modifies the clinical impact of TP53 functional loss on brain metastasis and survival in lung cancer
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景：
脑转移（BM）在 EGFR 突变型非小细胞肺癌（NSCLC）中很常见。外显子 19 缺失（Ex19del）和 L858R 是两种主要的 EGFR 敏感突变，它们在生物学行为、治疗反应和 CNS 复发模式上有所不同。TP53 是 EGFR 突变疾病中最频繁的共突变，已被证明与转移潜能增加和 CNS 进展相关，但其在 BM 情境下的亚型特异性效应仍不明确。我们研究了 TP53 功能缺失是否在 EGFR 亚型中对 BM 风险和 BM 后生存产生不同影响。
方法：
我们分析了 MSK-IMPACT 队列和 GENIE BPC 队列中的 NSCLC 患者。目标 1（BM 风险）：采用 BM 时间的 Cox 模型评估 EGFR 亚型、TP53 状态及其相互作用与就诊时 BM 和随访期间 BM 的关联，并对人口统计学、吸烟和分期进行了校正。目标 2（BM 后预后）：在具有影像学确认的 BM 或 CNS 的患者中，使用多变量 Cox 模型评估自 BM 诊断起的总生存期（OS），并对 BM 时机、颅内局部治疗、系统治疗代际和颅外转移负荷进行了校正。
结果：
在 152 例患者中，BM 时间分析同样显示 TP53 功能缺失的 BM 无进展生存期更短（校正 HR=1.65，P=0.11）。在 836 例伴 BM 的患者中，TP53 功能缺失预示更差的 OS（校正 HR=1.97，P=0.05），且这种不利效应在 EGFR L858R 和 Ex19del 亚型之间存在显著差异（交互作用 P=0.047）。在 Ex19del 肿瘤中，TP53 缺失与较差 OS 的关联较为轻微，而在 L858R 肿瘤中它与更差的结局强烈相关（中位 OS 34.7 vs 48.2 个月）。结果在各队列间一致，并且在排除低 VAF 的 TP53 变异后依然稳健。
结论：
TP53 功能缺失在不同 EGFR 突变亚型中具有不同的临床意义，与 Ex19del 疾病相比，它在 L858R 中既带来更高的脑转移风险，也带来显著更差的 BM 后生存。这些发现揭示了 EGFR 突变型 NSCLC 内部重要的亚型特异性异质性，并支持将 TP53 状态纳入 BM 风险评估和管理策略。
查看英文原文 English abstract
Background:
Brain metastasis (BM) is common in EGFR-mutant non-small cell lung cancer (NSCLC). Exon 19 deletion (Ex19del) and L858R, the two predominant EGFR sensitizing mutations, differ in biological behavior, therapeutic response, and CNS relapse patterns. TP53 is the most frequent co-mutation in EGFR-mutant disease, has been associated with increased metastatic potential and CNS progression, but its subtype-specific effects in the BM setting remain unclear. We examined whether TP53 functional loss differentially influences BM risk and post-BM survival in EGFR subtypes.
Methods:
We analyzed NSCLC patients from MSK-IMPACT cohort and GENIE BPC cohort. Aim 1 (BM risk): time-to-BM Cox models evaluated associations of EGFR subtype, TP53 status, and their interaction with BM at presentation and BM during follow-up, adjusting for demographics, smoking, and stage. Aim 2 (post-BM prognosis): Among patients with radiographically confirmed BM or CNS, overall survival (OS) from BM diagnosis was evaluated using multivariable Cox models adjusting for BM timing, local intracranial therapy, systemic treatment generation, and extracranial metastatic burden.
Results:
Among 152 patients, time-to-BM analyses similarly showed shorter BM-free survival for TP53 functional loss (adjusted HR=1.65, P=0.11). Among 836 patients with BM, TP53 functional loss predicted worse OS (adjusted HR=1.97, P=0.05), and this adverse effect differed markedly by EGFR L858R and Ex19del subtype (interaction P=0.047). In Ex19del tumors, TP53 loss had a modest association with poorer OS, whereas in L858R tumors it was strongly associated with worse outcomes (median OS 34.7 vs 48.2 months). Results were consistent across cohorts and robust to exclusion of low-VAF TP53 variants.
Conclusions:
TP53 functional loss has distinct clinical implications across EGFR mutation subtypes, conferring both higher risk of brain metastasis and significantly worse post-BM survival in L858R compared with Ex19del disease. These findings reveal important subtype-specific heterogeneity within EGFR-mutant NSCLC and support integrating TP53 status into BM risk assessment and management strategies.
利益披露 Disclosure
L. Li, None..
Y. Wong, None..
N. Yan, None..
Y. Zhou, None.